WARRENDALE, Pa., January 6, 2009 – MEDRAD, Inc., has signed a research agreement with the University of Zurich to study dynamic PET imaging with the MEDRAD Intego™ PET Infusion System. The researchers will utilize MEDRAD’s latest technology to more precisely control the radioactive dose delivered during PET imaging procedures.
Specifically, the study will examine patients with tumors in the chest or abdomen and compare standard quantitative techniques, such as standard uptake value (SUV), with more advanced kinetic and compartmental models. One of the primary goals of the research is to explore how controlled delivery technology can enable dynamic imaging by providing additional clinical utility and making these advanced techniques more practical. By enabling the benefit of repeatable infusion of the prescribed FDG dose to all subjects in the study, the Intego System is a key element in the research.
source: MEDRAD
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment